Phibro Animal Health Corporation

DB:PB8 Stock Report

Market Cap: €866.3m

Phibro Animal Health Management

Management criteria checks 2/4

Phibro Animal Health's CEO is Jack Bendheim, appointed in Jan 1988, has a tenure of 37.33 years. total yearly compensation is $4.75M, comprised of 49.6% salary and 50.4% bonuses, including company stock and options. directly owns 49.9% of the company’s shares, worth €432.28M. The average tenure of the management team and the board of directors is 6 years and 14.8 years respectively.

Key information

Jack Bendheim

Chief executive officer

US$4.8m

Total compensation

CEO salary percentage49.64%
CEO tenure37.3yrs
CEO ownership49.9%
Management average tenure6yrs
Board average tenure14.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Jack Bendheim's remuneration changed compared to Phibro Animal Health's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2025n/an/a

US$32m

Dec 31 2024n/an/a

US$19m

Sep 30 2024n/an/a

US$17m

Jun 30 2024US$5mUS$2m

US$2m

Mar 31 2024n/an/a

US$13m

Dec 31 2023n/an/a

US$15m

Sep 30 2023n/an/a

US$21m

Jun 30 2023US$3mUS$2m

US$33m

Mar 31 2023n/an/a

US$29m

Dec 31 2022n/an/a

US$36m

Sep 30 2022n/an/a

US$46m

Jun 30 2022US$4mUS$2m

US$49m

Mar 31 2022n/an/a

US$59m

Dec 31 2021n/an/a

US$53m

Sep 30 2021n/an/a

US$49m

Jun 30 2021US$4mUS$2m

US$54m

Mar 31 2021n/an/a

US$43m

Dec 31 2020n/an/a

US$44m

Sep 30 2020n/an/a

US$43m

Jun 30 2020US$3mUS$2m

US$34m

Mar 31 2020n/an/a

US$37m

Dec 31 2019n/an/a

US$38m

Sep 30 2019n/an/a

US$41m

Jun 30 2019US$3mUS$2m

US$55m

Mar 31 2019n/an/a

US$68m

Dec 31 2018n/an/a

US$73m

Sep 30 2018n/an/a

US$65m

Jun 30 2018US$3mUS$2m

US$65m

Compensation vs Market: Jack's total compensation ($USD4.75M) is above average for companies of similar size in the German market ($USD1.25M).

Compensation vs Earnings: Jack's compensation has increased by more than 20% in the past year.

CEO

Jack Bendheim (77 yo)

37.3yrs

Tenure

US$4,753,878

Compensation

Mr. Jack Clifford Bendheim has been the President and Chief Executive Officer of Phibro Animal Health Corporation since 1988 and March 2014, respectively and serves as its Chairman. Mr. Bendheim served as...

Leadership Team

NamePositionTenureCompensationOwnership
Jack Bendheim
Chairman37.3yrsUS$4.75m49.9%
€ 432.3m
Glenn David
Chief Financial Officer1.3yrsUS$2.40m0.074%
€ 641.2k
Larry Miller
Chief Operating Officer8.8yrsUS$3.42m0.074%
€ 641.2k
Daniel Bendheim
Executive VP of Corporate Strategy & Director11.2yrsUS$763.24kno data
Rob Aukerman
Advisor6yrsUS$752.70kno data
Jonathan Bendheim
Executive Vice President of Global Technology & People and Directorless than a yearno datano data
Judith Weinstein
Senior VP1.8yrsno datano data
Lisa Escudero
Senior Vice President of Human Resources8.2yrsno datano data
Ramon Fuenmayor
President South America Region7.9yrsno datano data
Samson Li
President of Asia Pacific Region2.1yrsno datano data
Todd Armstrong
President of North American Regionless than a yearno datano data
Michael Giambalvo
President of PhibroChem and Ethanol Performance Groupno datano datano data

6.0yrs

Average Tenure

55yo

Average Age

Experienced Management: PB8's management team is seasoned and experienced (6 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Jack Bendheim
Chairman41.3yrsUS$4.75m49.9%
€ 432.3m
Daniel Bendheim
Executive VP of Corporate Strategy & Director11.5yrsUS$763.24kno data
Jonathan Bendheim
Executive Vice President of Global Technology & People and Director6.8yrsno datano data
Samuel Gejdenson
Independent Non-Executive Director21.3yrsUS$60.00kno data
Mary Malanoski
Independent Non Executive Director21yrsUS$40.00kno data
Carol Wrenn
Independent Director14.8yrsUS$60.00k0.0025%
€ 21.4k
E. Corcoran
Independent Non-Executive Director17yrsUS$50.00k0.074%
€ 641.2k
Joyce Lee
Independent Directorless than a yearno datano data
Alejandro Bernal
Independent Director2.3yrsUS$50.00kno data

14.8yrs

Average Tenure

63yo

Average Age

Experienced Board: PB8's board of directors are seasoned and experienced ( 14.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/16 05:00
End of Day Share Price 2025/05/16 00:00
Earnings2025/03/31
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Phibro Animal Health Corporation is covered by 15 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Balaji PrasadBarclays
Matthew KornBarclays
Douglas TsaoBarclays